Mesoblast posts Q4 Ryoncil net revenue of US$36 million
Reuters2026/07/30 00:57- Mesoblast posted Ryoncil net revenue of US$36 million for the quarter ended June 30, 2026; US$115 million for the first full year post-FDA approval.
- Second-half Ryoncil net revenue totaled US$66.5 million; full-year net operating cash spend was US$43.8 million.
- Second-half operating cash spend was US$13.4 million; cash on hand was US$103 million at June 30, 2026.
- Drew US$50 million from a five-year facility to extinguish all maturing debt obligations.
- Commenced a registrational trial to extend Ryoncil into adults with steroid-refractory acute GvHD; up to 40 U.S. sites planned.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
